The biopharmaceutical company AbilityPharma, a member of CATALONIA.HEALTH, announced that the data of its Phase I/IIa ENDOLUNG trial evaluating Ibrilatazar (ABTL0812) in combination with chemotherapy (paclitaxel/carboplatin) for patients with stage III/IV squamous non-small cell lung cancer (sq-NSCLC) has been published in the Lung Cancer journal.
The trial was conducted at the Catalan Institute of Oncology (ICO) in Badalona, Girona and l’Hospitalet (Barcelona), Paoli-Calmettes Institute in Marseille, Virgen del Rocío University Hospital in Seville and Clinic University Hospital in Valencia.
The publication builds upon AbilityPharma’s previous research featured in the International Journal of Cancer (Leary et al., 2024). These advancements further consolidate the company’s leadership in the development of autophagy-mediated oncology drugs that selectively kill cancer cells while sparing normal cells.
Dr. Carles Domènech, AbilityPharma’s CEO & Co-Founder, stated, “This publication represents a crucial development in the study of new drugs and combinations for advanced squamous lung cancer. For AbilityPharma it is a significant milestone in our mission to deliver transformative treatments to cancer patients.”
Comments